Market Announcement

17 September 2019

Antisense Therapeutics Limited (ASX: ANP) – Trading Halt

Description

The securities of Antisense Therapeutics Limited ('ANP') will be placed in trading halt at the request of ANP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 19 September 2019 or when the announcement is released to the market.

Issued by

Cheng Tang
Senior Adviser, Listings Compliance (Melbourne)

Tuesday 17 September 2019

Kate Kidson
Principal Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited

Email: Kate.kidson@asx.com.au

Dear Kate,

Request for Trading Halt for Antisense Therapeutics Limited

In accordance with ASX Listing Rule 17.1, the Company requests an immediate trading halt in respect of its securities (ASX Code: ANP), pending release of an announcement in relation to the preliminary results of the Company's ATL1102 for DMD Phase II clinical trial.

In requesting the trading halt, the Company provides the following information:

- The trading halt is requested in respect of finalising of an announcement following the Company's board review of the preliminary Phase II trial results this morning;
- Unless otherwise requested by the Company, ANP requests the trading halt to remain in place until the earlier of the release of an announcement or the morning of Thursday 19 September 2019; and
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely,



Phillip Hains
Company Secretary

6-8 Wallace Avenue
Toorak, Victoria
Australia 3142

Antisense Therapeutics Limited
ABN 41 095 060 745

Phone: + 61 (0)3 9827 8999
Facsimile: + 61 (0)3 9827 1166

www.antisense.com.au